BackPhaseBio Pharmaceuticals Overview
PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals Debt to Equity

Valuation check: PHAS's debt-to-equity ratio is -0.06, below the Healthcare sector average of 0.93.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

-0.06

Debt to Equity

-0.06

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Average Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

PhaseBio Pharmaceuticals (PHAS) FAQ

As of the most recent data, PHAS shows a debt-to-equity ratio of -0.06. That is below the Healthcare sector average of 0.93. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.93. PhaseBio Pharmaceuticals is at -0.06, which is lower that average. That is roughly 106.2% below the sector mean. Use the comparison chart on this page to see how PHAS stacks up against individual peers as well.

Investors watch PHAS's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. PhaseBio Pharmaceuticals's latest reading is -0.06. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently -0.06) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.93, while PHAS is at -0.06. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.